Efficacy and Safety of Upadacitinib for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.

Ahmed Hamdy G Ali Asmaa Elganady Mahmoud Diaa Hindawi Ahella Ismail A Mousa Hatem Abdelmoneim EldeebAhmed Ramadan FatiemYulia Skopina

Published in: Current rheumatology reviews (2024)

Upadacitinib 15 mg showed satisfactory and promising efficacy in the treatment of AxSpA, with no difference in safety profile compared to the placebo.

Keyphrases

ankylosing spondylitis
disease activity
randomized controlled trial
systemic lupus erythematosus
smoking cessation